

# Specimens:			Depot:	
Collect Date:	Time:	Ву:	ABN Signed:	*STAT*
MD #		۸ #۰		

	i wii v #.	Λπ.
REQUIRED (PRINT OR PAT	ENT LABEL)	
Name(Last, First, MI)		Practice Name
Date of Birth Sex:(0	onoic) ivi	Address
Street Address		Address2
Street Address 2		
City, State, Zip		City, State, Zip
Phone Number Client Number		Phone#
Indicate primary (1) and secondary (2) insurance		Ordering
Blue Cross/ShieldChild Health PlusMVP		Provider
Medicare Blue ChoiceMedicareAetna		
Other		Results to: Fax Results to: ng Provider's Signature
Primary Contract #:		osis Mandatory: Signs/Symptoms or ICD9 Codes
Subscriber's Name:		ed for screening, list test name here and write "SCREENING" after it
Relationship to Subscriber:	Send	Additional Reports To: (Full Name/Address)
2. Secondary Contract#		iance is Mandatory and Regulated. For the laboratory to bill properly and receive payment for tests ordered
Subscriber's Name:	each t	dicare Beneficiaries, specific ICD-9 code(s) or a descriptive diagnosis must be included on each patient for est ordered. It is critical that the diagnosis provided to the lab is consistent with those recorded in the patient
Relationship to Subscriber:	medica	al record on the date of service.
Clinical History	Malagular Diag	nastia I ahayatawa
Molecular Oncology (No Consent F	Molecular Diag	nostic Laboratory
36680 B-CELL GENE REARRANGEN 37343 T-CELL GENE REARRANGEN 22220 M-bcr / abl (CML-type) Translor 24710 NPM1 (nucleophosmin) 42253 JAK2 V617F Mutation 32206 FLT3 ITD Codon 835/836	DENT (PCR) cation (quantitative) Test must be ordered STAT	47831 Factor V Leiden
	Pre-Transplant Patient Specimen Donor Specimen	23052 Prothrombin G20210A Mutation 39231 HFE C282Y, H630, AND S65C
	Post-Transplant Patient Specimen	Mutations (Hemochromatosis)
If this is a Doct Transmi	ed more than 1 transplant? Iant specimen, has the patient	38610 LCHAD Deficiency E474Q Mutation
Yes No If this is a Post-Transpi been transfused in the		30476 CLN3 Gene Deletion
Recipient Name		(Batten Disease)
Date of Birth		
Transplant Date		
Donor Name/ID		Consent for Physician to add Factor V Leiden if
Date of Birth		APCR is <2.1
Related Unrelated		
Consen	t for Molecular Genet <u>ic Te</u>	sting (Required by New York State)
	his form and discussed it with my he	ealth care provider. I have been given an opportunity to ask questions and
I give my consent for genetic testing, and	-	I give my consent for the use of remaining sample for research
Patient/Legal Guardian:	Date:	/ Health Care Provider:

Molecular Diagnostic Consent Patient Information Sheet

Strong Health

University of Rochester/Strong Memorial Hospital Clinical Laboratories 601 Elmwood Avenue; PO Box 608; Rochester, NY 14642

Patient Name	Date of birth

Informed Consent for Genetic Testing

- These tests look for changes in DNA, chromosomes, genes or gene products that are know to be associated
 with risk of specific diseases. The purpose of these tests is to help your doctor more accurately diagnose your
 current condition and/or future risk of disease.
- 2. In addition to assisting in making a diagnosis, these tests may reveal a genetic pre-disposition for one or more of these diseases. You may wish to get genetic counseling before consenting to this test. If a positive result is obtained, additional testing and/or genetic counseling follow-up may be advised.
- 3. Your doctor has ordered one or more of the following tests:

FACTOR V LEIDEN - This is a test for a variation in another gene that affects blood clotting. If this variant is present, it may indicated a higher than average risk for developing blood clots.

PROTHROMBIN GENE MUTATION - This is a test for a variation in another gene that affects blood clotting. If this variant is present, it may indicate a higher than average risk for developing blood clots.

HEMOCHROMATOSIS MUTATIONS - This is a test for a variation in a gene that controls iron storage in the body, and helps to diagnose hereditary hemochromatosis, a disease of iron overload.

CLN3 gene deletion - This test detects the most common deletion associated with Batten disease (Juvenile Ceroid Lipofuscinosis). It will help in evaluating the risk of having or being a carrier of this disease. A lack of the mutation does not absolutely rule out the disease, but makes it much less likely.

LCHAD deficiency E474Q mutation - This test detects the most common mutation that causes deficiency of an enzyme that metabolizes fats. It will help in evaluating the risk of having or being a carrier of this disease. A lack of the mutation does not absolutely rule out the disease, but makes it less likely.

- 4. The results of these genetic tests assist in diagnosis, but do not by themselves permit diagnosis of a disease condition. Genetic testing is ordinarily highly accurate; however, in some cases results may not be obtained or may be inconclusive. Only certain variations in these genes are known and available for testing, so a "normal" result in these genetic tests cannot guarantee that you do not have or will not develop a particular disease. Some genetic tests are only done by a few laboratories in the world, and may need to be sent to out of state laboratories that are not certified by New York State Health Department. In some instances, the clinical utility of the test may not be established.
- 5. Because interpretation of genetic test results is complex, the test results will be provided to your physician who will inform you of the results. To the extent permitted by law, all of the records and results of this testing are confidential and will not be released to anyone other than you, your referring doctors, and Strong Memorial Hospital Medical Records without your consent.
- 6. Besides providing excellent medical care, one of the missions of the University of Rochester and Strong Memorial Hospital is advancing medical science. Our doctors learn about better ways to care for patients and improve the health of people. No tests other than those authorized will be performed on your sample, and your sample will be destroyed after testing or not more than sixty days after the sample is taken, unless you consent to allow us to use the remaining sample for research. With your consent, our researchers will be able to use the remaining part of blood samples not needed for the specific tests above for approved development of new or improved laboratory tests. Names and other identifying information are kep strictly confidential. Samples with consent for research are stored indefinitely. We sometimes conduct follow-up studies based on new medical information. If you are eligible, someone will contact you personally. Participation in such studies is voluntary.